Characteristics of patients at the 12-year follow-up visit and their medication according to their 12-year adherence
| 12-year adherence | |||
| Good adherence# | Poor adherence¶ | p-value | |
| Age years mean±sd | 61±12 | 58±14 | 0.065§ |
| Female sex | 52 (63.4%) | 56 (56.6%) | 0.365ƒ |
| BMI kg·m−2 | 28.1 (24.3–31.3) | 28.4 (24.6–31.2) | 0.640## |
| Smokers+ | 40 (48.8%) | 51 (51.5%) | 0.766ƒ |
| Smoking history pack-years | 18 (9–33) | 17 (6–29) | 0.407## |
| Smoking history ≥10 pack-years and post-BD FEV1/FVC <0.7 | 12 (30%) | 21 (42%) | 0.276ƒ |
| Number of comorbidities | 1 (0–3) | 1 (0–2) | 0.487## |
| Daily SABA | 13 (15.9%) | 8 (8.1%) | 0.161ƒ |
| Daily LABA | 54 (65.9%) | 41 (41.4%) | 0.002ƒ |
| Daily LTRA | 18 (22%) | 8 (8.2%) | 0.011ƒ |
| Daily theophylline | 4 (4.9%) | 0 (0%) | 0.040ƒ |
| Daily tiotropium | 5 (6.1%) | 3 (3.0%) | 0.471ƒ |
| Daily add-on drug | 57 (69.5%) | 44 (44.4%) | 0.001ƒ |
| Average prescribed ICS daily dose over 12 years µg budesonide equivalents | 810 (611–1043) | 805 (610–967) | 0.496## |
| Average dispensed ICS daily dose over 12 years µg budesonide equivalents | 803 (616–1075) | 320 (146–472) | <0.001## |
Data are presented as n (%) or median (interquartile range), unless otherwise stated. BMI: body mass index; BD: bronchodilator; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; SABA: short-acting β2-agonist; LABA: long-acting β2-agonist; LTRA: leukotriene receptor antagonist; ICS: inhaled corticosteroid. #: ≥80% adherence, n=82; ¶: <80% adherence, n=99; +: including ex-smokers; §: independent-samples t-test; ƒ: Fisher's exact test; ##: Mann–Whitney U-test.